HIV vaccine - Progenics

Drug Profile

HIV vaccine - Progenics

Alternative Names: HIV gp140 vaccine - Progenics; ProVax

Latest Information Update: 23 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aaron Diamond AIDS Research Center; Progenics Pharmaceuticals; Weill Cornell Medical College
  • Developer Progenics Pharmaceuticals
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 15 Mar 2012 Discontinued - Preclinical for HIV infections in USA (Parenteral)
  • 23 Nov 2011 HIV vaccine - Progenics is available for licensing as of 09 Nov 2011.
  • 12 Apr 2010 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top